Hrt Financial LP Crinetics Pharmaceuticals, Inc. Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$25.62 - $37.07 $330,831 - $478,684	12,913 New	12,913 $459,000
Q2 2022 Aug 12, 2022	SELL	$16.49 - $27.64 $211,863 - $355,118	-12,848 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $220,343 - $363,726	12,848 New	12,848 $282,000
Q1 2020 May 15, 2020	SELL	$11.52 - $26.46 $121,904 - $279,999	-10,582 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.24 - $25.09 $161,269 - $265,502	10,582 New	10,582 $265,000

244

78.2M

268K

197K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.73B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.